Navigation Links
Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
Date:2/9/2009

women who had been using a topical microbicide or oral antiretrovirals as an HIV preventive measure when they acquired HIV infection.

A second large trial testing the safety and effectiveness of the 0.5% dose of PRO 2000 is currently underway. This trial is being sponsored by the United Kingdom's Medical Research Council (MRC) and conducted by the Microbicides Development Programme (MDP), an international partnership of researchers established to develop microbicides for the prevention of HIV transmission. Study MDP 301 is a multi-national, randomized, double-blind, placebo-controlled Phase III trial designed to examine the safety and effectiveness of PRO 2000 in preventing HIV infection in women. As in the HPTN 035 trial, all participants receive free condoms, risk-reduction counseling, and treatment for sexually transmitted infections. Approximately 9,400 women have been enrolled at study sites in South Africa, Tanzania, Uganda, and Zambia. The trial is expected to be completed during the summer of 2009.

Should PRO 2000 be shown conclusively to be safe and effective, Indevus intends to seek worldwide marketing approvals, and plans to work with government agencies and other organizations to help ensure affordable access to the product in resource-limited settings where the need is greatest.

According to statistics from UNAIDS and the U.S. Centers for Disease Control and Prevention, nearly half of the 33 million people living with HIV/AIDS worldwide are women. Most HIV infections in women are due to heterosexual intercourse. Moreover, women are twice as likely as their male partners to acquire HIV during sex, due in part to biological factors that make women more vulnerable. Although correct and consistent use of male condoms has been shown to prevent HIV infection, women often cannot negotiate condom use with their male partners. A safe and effective vaginal microbicide could offer a readily available app
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
2. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
3. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
4. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
5. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
6. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
7. Indevus Announces Submission of New Drug Application
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
10. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
11. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, 2015 ... 47.54 billion by 2020, according to a new study by Grand ... II diabetes and the presence of high unmet needs in emerging ... China are expected to be two of the most ... lifestyle induced diseases such as obesity and growing global geriatric population ...
(Date:6/29/2015)... CITY, Mo. , June 29, 2015  Missouri ... the 2015 first quarter data from the state,s real-time, ... (NPLEx). States across the United ... Missouri one of 31 across the country ... attempted pseudoephedrine (PSE) purchases at the point of sale.  ...
(Date:6/29/2015)... KING OF PRUSSIA, Pa. , June 29, 2015 ... Alsharabati, MD, University of Alabama at Birmingham, ... 2015 Interlaken Leadership Award for ... global awards program provides monetary grants and/or product supply ... potential role of immunoglobulin (Ig) therapy in the treatment ...
Breaking Medicine Technology:Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 2Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 3Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 4CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient 2CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient 3
... 5, 2011 In its April issue, published this ... magazine has announced the winners of the fourteenth annual ... (Logo:  https://photos.prnewswire.com/prnh/20101214/LA16070LOGO) Sponsored by MD+DI ... the premier awards program for the medical technology community. ...
... April 5, 2011 RESMED INC. (NYSE: RMD ... will release its results for the third quarter and nine ... press release with ResMed,s results will be issued after 1:00 ... call and webcast to review its results, market trends, and ...
Cached Medicine Technology:37 Innovative Products Win Medical Design Excellence Awards 237 Innovative Products Win Medical Design Excellence Awards 337 Innovative Products Win Medical Design Excellence Awards 4ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2011 Results 2
(Date:6/29/2015)... , ... June 30, 2015 , ... ... set of revised Guidelines for Neuro Musculoskeletal Thermography and Sympathetic Skin Response Studies.* ... Guidelines that were first published in 2006, are intended to aid physicians and ...
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, one of ... John A. Mitamura, MD., PhD into their world-class multidisciplinary team of physicians and ... Long Beach , Irwindale and La Tijera-Los Angeles. , Orthopedic surgeons of ...
(Date:6/29/2015)... ... , ... Mediaplanet has released the first edition of “Heart ... glossy, full-color special section hit newsstands Friday, June 26th, and was distributed within ... with an estimated readership of 1.3 million. The digital component is being distributed ...
(Date:6/29/2015)... YORK, NEW YORK (PRWEB) , ... June 29, ... ... sleep apnea (OSA) is now being offered at NewYork-Presbyterian/Weill Cornell Medical Center. The ... Drug Administration and is an alternative to continuous positive airway pressure (CPAP), the ...
(Date:6/29/2015)... ... June 29, 2015 , ... National HealthCare Associates ... customer service for the 40-center nursing home group. Sixteen of their centers were ... the United States in one or more customer service areas. Those centers received ...
Breaking Medicine News(10 mins):Health News:American Academy of Thermology Publishes Revised 2015 Guidelines for Neuro-Musculoskeletal Thermography and Sympathetic Skin Response Studies 2Health News:American Academy of Thermology Publishes Revised 2015 Guidelines for Neuro-Musculoskeletal Thermography and Sympathetic Skin Response Studies 3Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Mediaplanet partners with USA TODAY and Kris Letang to raise awareness about the risk of heart attack and stroke 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4
... Foundation site trends indicating measles risk remains highWASHINGTON, ... states - California, Pennsylvania, Maryland and Iowa - ... children living in the United States as well ... of the disease.(Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ...
... disease, experts say , , FRIDAY, April 17 (HealthDay News) -- ... (PTU) in children has been endorsed by the Endocrine Society. ... 9 New England Journal of Medicine , two experts ... and should no longer be used as a first-line treatment ...
... The following statement may be attributed to Amy ... Research: "We are pleased that the National Institutes of ... of creating federal guidelines to remove restrictions on embryonic ... great promise, today,s draft guidelines that would allow federal ...
... makes prevention more difficult, study finds, , , FRIDAY, April ... commit suicide have been diagnosed with a mental disorder. ... death certificates list mental disorder as a contributing factor, ... it more difficult for health-care policymakers to create prevention ...
... the United States Great Depression of 1929 has the ... and well-being across the parameters of occupational, spiritual, emotional, ... pace, people are at risk for suffering lowered self ... Miami,s St. Thomas University Counseling Programs - ...
... Offers SolutionMURFREESBORO, Tenn., April 17 Medication mistakes at ... to a recent national study, and the need for ... to Shane Reeves, D. Pharm and co-owner of Reeves-Sain.Reeves ... system of bottles to a clearer, more easily managed ...
Cached Medicine News:Health News:U.S. Measles Outbreaks Highlight Global Need 2Health News:Drug May Be Dangerous for Kids With Graves' Disease 2Health News:Death Certificates Incomplete for Suicide Victims 2Health News:Good News for Tough Times: Small, Private University Responds to Today's Economic Challenges 2Health News:Medication Mismanagement Is a Growing Danger 2
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
... Deformity System unites the clinical experience ... and Isola with revolutionary technology developed ... unsurpassed versatility, simplicity and security. Frontier ... versatility for treating a deformity from ...
Medicine Products: